Difficulties created by chronic dependence on foreign labs led to an innovative decision: Brazil now has a state-owned company exclusively to research, develop and produce medicinal products derived from blood.
Hemobrás, the Brazilian blood product and biotechnology company, is close to completing construction of a plant in Pernambuco. When the facility is up and running, it will produce medications to safeguard the lives of hemophiliacs and people with genetic immunodeficiency, cancer, cirrhosis, AIDS and severe burns treatment through the Single Health System.